Search Results

You are looking at 11 - 20 of 868 items for :

  • Refine by Access: All x
Clear All
Full access

Therapeutic Advances in Relapsed or Refractory Multiple Myeloma

Kenneth C. Anderson

gains expected from maintenance therapy. “But new approaches are still needed to treat and ultimately prevent relapse. Fortunately, there are exciting novel targeted agents on the horizon,” he said. First-Line Combinations After the second

Full access

Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL

Aliza Gardenswartz and Mitchell S. Cairo

Children, adolescents, and young adults (CAYAs) with newly diagnosed B-cell non-Hodgkin’s lymphoma (B-NHL) enjoy excellent overall survival (OS) with current frontline chemoimmunotherapy. 1 – 3 However, those with relapsed and/or refractory (R

Full access

Management of Relapsed/Refractory Multiple Myeloma

Presented by: Natalie S. Callander

experience relapses. Clinicians are tasked with selecting the best treatment options for these progressions from among a growing cascade of regimens. Explaining this treatment landscape at the NCCN 2023 Annual Conference was Natalie S. Callander, MD

Full access

The Role of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma

Leona Holmberg and David G. Maloney

Treatment for Hodgkin lymphoma (HL) has improved so that most patients, even those with high-risk disease, are now cured with primary therapy. 1 , 2 However, for patients with primary refractory disease, or those experiencing relapse after

Full access

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Mitul Gandhi and Adam Petrich

approaching those achieved in patients who are HIV-negative. 6 - 10 Recent studies suggest a similar trend in HIV-cHL. 11 , 12 However, a paucity of prospective data exists for the treatment of relapsed disease, although modest success has been reported with

Full access

Strategies for Management of Relapsed or Refractory Hodgkin Lymphoma

Leo I. Gordon

“There are a number of salvage chemotherapy regimens in relapsed or refractory [R/R] Hodgkin lymphoma [HL],” revealed Leo I. Gordon, MD, Abby and John Friend Professor of Cancer Research and Professor of Medicine, Division of Hematology

Full access

Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma

Presented by: Natalie S. Callander

As new drugs continue to be approved for the treatment of multiple myeloma (MM) at a rapid pace, there have never been more treatment choices available for patients with relapsed disease. Except for those with the highest-risk disease or plasma

Full access

The Emerging Role of Novel Therapies for the Treatment of Relapsed Myeloma

Paul G. Richardson, Teru Hideshima, Constantine Mitsiades, and Kenneth C. Anderson

thalidomide analogs in human multiple myeloma cells: therapeutic implications . Blood 2002 ; 99 : 4525 – 4530 . 16. Jagannath S Barlogie B Berenson J . A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma . Br J Haematol

Full access

Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors

Presented by: Brian T. Hill

In recent years, the treatment landscape for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has seen significant advancements, ushering in an era of targeted therapies that have transformed patient outcomes

Full access

Incorporating Immunotherapeutic Strategies in the Management of Relapsed/Refractory Multiple Myeloma

Presented by: Shaji K. Kumar

“Immunotherapy has changed the treatment paradigm for myeloma,” having significantly improved overall survival (OS) in patients with newly diagnosed and relapsed/refractory (R/R) disease, said Shaji K. Kumar, MD, Professor of Medicine, Research